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Abstract
Background:  Extracellular nucleotides (ATP, ADP, UTP and UDP) exert a wide range of
biological effects in blood cells mediated by multiple ionotropic P2X receptors and G protein-
coupled P2Y receptors. Although pharmacological experiments have suggested the presence of
several P2 receptor subtypes on monocytes and lymphocytes, some results are contradictory. Few
physiological functions have been firmly established to a specific receptor subtype, partly because
of a lack of truly selective agonists and antagonists. This stimulated us to investigate the expression
of P2X and P2Y receptors in human lymphocytes and monocytes with a newly established
quantitative mRNA assay for P2 receptors. In addition, we describe for the first time the expression
of P2 receptors in CD34+ stem and progenitor cells implicating a potential role of P2 receptors in
hematopoietic lineage and progenitor/stem cell function.
Results: Using a quantitative mRNA assay, we assessed the hypothesis that there are specific P2
receptor profiles in inflammatory cells. The P2X4  receptor had the highest expression in
lymphocytes and monocytes. Among the P2Y receptors, P2Y12 and P2Y2 had highest expression in
lymphocytes, while the P2Y2 and P2Y13 had highest expression in monocytes. Several P2 receptors
were expressed (P2Y2, P2Y1, P2Y12, P2Y13, P2Y11, P2X1, P2X4) in CD34+ stem and progenitor cells.
Conclusions: The most interesting findings were the high mRNA expression of P2Y12 receptors
in lymphocytes potentially explaining the anti-inflammatory effects of clopidogrel, P2Y13 receptors
in monocytes and a previously unrecognised expression of P2X4 in lymphocytes and monocytes. In
addition, for the first time P2 receptor mRNA expression patterns was studied in CD34+ stem and
progenitor cells. Several P2 receptors were expressed (P2Y2, P2Y1, P2Y12, P2Y13, P2Y11, P2X1,
P2X4), indicating a role in differentiation and proliferation. Thus, it is possible that specific
antibodies to P2 receptors could be used to identify progenitors for monocytes, lymphocytes and
megakaryocytes.
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Background
Extracellular nucleotides (ATP, ADP, UTP and UDP) exert
a wide range of biological effects in blood cells mediated
by multiple ionotropic P2X receptors and G protein-cou-
pled P2Y receptors [1-3]. So far, the P2Y family is com-
posed of eight cloned and functionally distinct subtypes
(P2Y1, P2Y2, P2Y4, P2Y6, P2Y11, P2Y12, P2Y13, P2Y14)
[4,5]; the P2X family is composed of seven cloned sub-
types (P2X1-P2X7) [6,7].
We have previously quantified P2 receptor mRNA expres-
sion in platelets (representing megakaryocyte expression),
and demonstrated a selective expression of the ADP recep-
tors P2Y12 and P2Y1, together with the ATP receptor P2X1
[8]. This is consistent with the clinical effect of the P2Y12
antagonist clopidogrel for the prevention of myocardial
infarctions in patients with acute coronary syndromes
[9,10]. However, virtually every hematopoietic cell is
responsive to nucleotides [2]. Because effects as different
as proliferation, differentiation, chemotaxis and release of
cytokines are regulated by nucleotides, they could play a
role in the atherosclerotic inflammatory process. Human
lymphocytes, monocytes and macrophages constitute an
important line of defence upon infection and exposure to
inflammatory stimuli [11]. Circulating blood monocytes
become activated, migrate to tissues, and undergo differ-
entiation into macrophages during inflammation [12].
Monocytes have been shown to express several P2Y recep-
tors and up-regulation of P2X7 receptor mRNA in mono-
cytes has been observed upon cell differentiation to
macrophages [13,14].
Although pharmacological experiments have suggested
the presence of several P2 receptor subtypes on monocytes
and lymphocytes, some results are contradictory [1,2].
Few physiological functions have been firmly established
to a specific receptor subtype, partly because of a lack truly
selective agonists and antagonists. This stimulated us to
investigate the expression of P2X and P2Y receptors in
human lymphocytes and monocytes with a newly estab-
lished quantitative mRNA assay for P2 receptors [8,15]. In
addition, we describe for the first time the mRNA expres-
sion of P2 receptors in CD34+ stem and progenitor cells
implicating a potential role of P2 receptors in hematopoi-
etic lineage and progenitor/stem cell function.
Results and Discussion
Our previous studies of P2 receptor mRNA expression in
man with real-time PCR has shown a good resemblance
with pharmacological and physiological experiments in
vascular smooth muscle cells, endothelial cells and plate-
lets [8,15]. It is therefore likely that our present mRNA
findings in inflammatory, progenitor and stem cells are
physiologically relevant. The lack of selective agonists and
antagonists for most of the receptor subtypes combined
with the absence of studies focused on several of the more
recently cloned receptors makes the findings important.
Furthermore, no pharmacological studies have been
made on CD34+ stem and progenitor cells.
Expression of P2Y receptors in lymphocytes
In lymphocytes, all the target genes P2Y1, P2Y2, P2Y4,
P2Y6, P2Y11, P2Y12, and P2Y13 could be detected (n = 6).
To illustrate expression of the P2 receptors relative to each
other the P2Y1 receptor was used as calibrator for the oth-
ers, i. e. the other receptors were expressed as a ratio of the
P2Y1. Among the P2Y receptor subtypes the P2Y12 and
P2Y2  had highest expression (Figure 1A). The lowest
expressed P2Y receptor was P2Y4.
Extracellular nucleotides and their P2 receptors are
involved in the regulation, proliferation but also apopto-
sis and cell death in lymphocytes and monocytes [3,16].
Previous studies have shown that ATP, ADP, UTP and
UDP stimulate phospholipase C and Ca2+ release from
intracellular stores, that fits well with the highly expressed
P2Y2 receptor, together with the lesser expressed P2Y1 and
P2Y6 receptors. ATP and ADP, but not UTP, can also
increase cAMP [17]. This is in agreement with the P2Y11
receptor that had the third highest mRNA expression.
The most interesting finding was that P2Y12 had the high-
est expression among the P2Y receptors in lymphocytes. It
is not likely that this is the result of platelet contamina-
tion, because platelets contain very low amounts of RNA.
To the best of our knowledge, there are no studies that
have examined the effects of P2Y12 on lymphocytes, even
though selective antagonists exist. It is expected to inhibit
cAMP generation and may activate lymphocytes. This
could explain the antiinflammatory effect of clopidogrel.
Clopidogrel is a P2Y12 antagonist used in the clinic as a
platelet aggregation inhibitor that reduces thrombotic car-
diovascular events such as myocardial infarctions. How-
ever, it has also been shown to reduce CRP, even though
aspirin in antiplatelet doses lacks this effect [18]. This
effect may be mediated via P2Y12  receptors in
lymphocytes.
Expression of P2X receptors in lymphocytes
The most abundant P2X receptor in lymphocytes was the
P2X4 receptor. As showed in Figure 1B, the expression of
P2X4 was 3.2 times higher than P2Y1. The expression of
P2X4 was significantly higher than the expression of the
other P2X receptors; P2X1 (P < 0.001) and P2X7(P < 0.01).
Selective pharmacological tools to discriminate between
P2X receptors are scarce. Nevertheless, several studies have
suggested the importance of P2X7 in lymphocyte regula-
tion. However, B lymphocytes stimulated with ATP do not
undergo the typical increase in permeability up to 900 DaBMC Immunology 2004, 5:16 http://www.biomedcentral.com/1471-2172/5/16
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that is typical for the P2X7 receptor. On the other hand,
P2X7 mediated effects on Ba2+ and ethidium influx, phos-
pholipase D activity and shedding of L-selectin have been
blocked by the P2X7 selective antagonist KN-62 in human
lymphocytes [19]. Thus it is a surprising finding that the
P2X4 receptor was the highest expressed subtype in lym-
phocytes at the mRNA level. Even though we have demon-
strated that more than 90% of the preparation consists of
lymphocytes (see methods), it is possible that a small con-
tamination of monocytes may have influenced the results,
at least regarding P2X4  receptor mRNA expression,
because of its high expression levels in monocytes. P2X4
receptors have indeed been demonstrated at the protein
level in human B lymphocytes by confocal immunohisto-
chemistry, in which P2X1, P2X4 and P2X7 were detected at
the protein level [20]. However, the P2X4 receptor staining
was the most variable of the P2X receptors with weak to
moderate levels of staining in a large proportion of cells in
three patients and weak levels in only a minority of the
cells from the other three patients examined [20].
Expression of P2Y receptors in monocytes
Again, the P2Y1 expression was used as calibrator for the
others, i. e. the other receptors were expressed as a ratio of
the P2Y1. Among the P2Y receptors, the P2Y2, P2Y13 and
P2Y11 had highest expression (Figure 2A, n = 6). The pres-
ence of P2Y receptor mRNA in monocytes and lym-
phocytes is in agreement with previous studies using
regular RT-PCR [21].
Extracellular nucleotides stimulate interleukin secretion,
iNOS-generation in monocytes, are involved in differenti-
ation, cytotoxicity and killing of pathogens. All mono-
cyte/macrophage cell lines express P2Y receptors coupled
to IP3 generation and intracellular Ca2+ release, but the
individual subtypes have not been investigated in detail in
monocytes [2,3]. However, both ATP and UTP are active
agonists, which is in agreement with the highest mRNA
expression of the ATP/UTP receptor P2Y2 (Fig 2). ATP
mediated increase in cAMP has suggested the presence of
P2Y11, with a suggested role in maturation of human
monocyte-dendritic cells [22]. A relatively high expression
of P2Y11 was confirmed in our experiments. Interestingly,
the P2Y13 had even higher mRNA levels. To our knowl-
edge, no experiments have addressed the presence of this
cAMP inhibitory ADP receptor in monocytes. In fact, it
has been an unresolved issue in what tissue this receptor
is expressed. High levels in the spleen could be in agree-
ment with monocyte expression [23]. Thus, the presence
of P2Y2 and P2Y11 receptors are confirmed as expected,
Relative P2 gene expression in lymphocytes Figure 1
Relative P2 gene expression in lymphocytes. A, Bar graph shows relative P2Y1, P2Y2, P2Y4, P2Y6, P2Y11, P2Y12 and P2Y13 
receptor gene expression normalized to GAPDH. B, Bar graph shows relative P2X1, P2X4 and P2X7 receptor gene expression 
normalized to GAPDH. P2Y1 was chosen to be calibrator.
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with the interesting addition of P2Y13 receptors. Future
experiments addressing the physiological role of P2Y13
receptors in monocytes are needed.
Expression of P2X receptors in monocytes
Early studies demonstrated that ATP activates a receptor
on macrophages that increase cell permeability eventually
leading to cell death [2,3]. P2X7 receptor transfection con-
fers susceptibility to ATP-dependent permeabilization
and ATP-resistant clones lack the P2X7 receptor, demon-
strating that it is present on macrophages and necessary
for permabilization. However, it is not known whether
P2X7 is the only constitutive subunit or if it assembles
with other subunits.
As showed in Figure 2B, P2X4 was by far the highest
expressed P2 receptor in monocytes and the P2X1 (P <
0.01) and P2X7 (P < 0.01) had lower levels. Thus, unex-
pectedly the P2X7 receptor was not the highest expressed
P2X receptor in monocytes. This is in agreement with
patch-clamp experiments suggesting that other P2X recep-
tors are involved [24]. Interrelation of these experiments
has suggested the contribution of P2X4 receptors, which is
supported by our findings [25]. It should be noted that all
the three P2X receptors were expressed at very high levels
compared to other cell types (30-fold more than the cali-
brator gene for P2X4 and 6–7-fold more for P2X1 and
P2X7). A physiological role for all three subtypes can
therefore be expected.
Expression of P2 receptors in CD34+ stem and progenitor 
cells
CD34+ stem and progenitor cells are receiving an increas-
ing attention because of their extensive self-renewal and
multilineage differentiation ability making them attrac-
tive for cellular therapy [26]. Knowledge of their P2 recep-
tor expression could be used for directing differentiation
or for further subtype selection of early progenitors types.
There are no previous pharmacological or expression
studies of P2 receptors on human CD34+ stem and pro-
genitor cells. We found expression of several P2Y recep-
tors, especially P2Y1 and P2Y2 (Figure 3A, n = 3). This
indicates that both ATP and UTP are agonists for CD34+
stem and progenitor cells and may stimulate IP3 and intra-
cellular Ca2+ release.
Among the P2X receptors the P2X1 receptor had the high-
est expression followed by P2X4 (P2X1 had significantly
higher expression than P2X7, P < 0.05) (Figure 3B, n = 3),
suggesting a potential role of these receptors in regulation
of stem and progenitor cells. P2Y1, P2Y2 and P2X1 recep-
tors have all been shown to stimulate proliferation, but
also to be able to mediate apoptosis [26]. Such roles could
be of major importance in the highly proliferative CD34+
Relative P2 gene expression in monocytes Figure 2
Relative P2 gene expression in monocytes. A, Bar graph shows relative P2Y1, P2Y2, P2Y4, P2Y6, P2Y11, P2Y12 and P2Y13 
receptor gene expression normalized to GAPDH. B, Bar graph shows relative P2X1, P2X4 and P2X7 receptor gene expression 
normalized to GAPDH. P2Y1 was chosen to be calibrator.
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stem and progenitor cells. Antagonists or agonists of these
receptors could be used to control their differentiation or
proliferation.
Conclusions
The P2X4 receptor had the highest mRNA expression in
lymphocytes and monocytes. Among the P2Y receptors,
P2Y12 and P2Y2 had highest expression in lymphocytes,
while the P2Y2  and P2Y13  had highest expression in
monocytes. The most interesting findings were the high
mRNA expression of P2Y12  receptors in lymphocytes
potentially explaining the anti-inflammatory effects of
clopidogrel, P2Y13 receptors in monocytes and a previ-
ously unrecognised expression of P2X4 in lymphocytes
and monocytes. In addition, for the first time P2 receptor
mRNA expression patterns have been studied in CD34+
stem and progenitor cells. Several P2 receptors were
expressed (P2Y2, P2Y1, P2Y12, P2Y13, P2Y11, P2X1, P2X4),
indicating a role in differentiation and proliferation. Thus,
it is possible that specific antibodies to P2 receptors could
be used to identify progenitors for monocytes, lym-
phocytes and megakaryocytes.
Methods
The studies were approved by the local Ethics Committee
of the Lund University and were conducted according to
the principles of the Declaration of Helsinki.
Preparation of monocytes and lymphocytes
Peripheral blood was drawn from each of 6 healthy volun-
teers (after informed consent) into heparin vials. The
mononuclear cells were isolated by density gradient cen-
trifugation on Lymphoprep™ (Axis Shield Poc AS, Oslo,
Norway) at 605 g for 30 minutes. The lymphocytes and
monocytes thus obtained were washed three times in
RPMI 1640 medium with L-glutamine (Gibco/BRL, Life
Technologies Ltd, Paisleys, Scotland) and 0.1% human
serum albumin (Sigma, St Louise, MO, USA), (medium),
and centrifuged each time at 605 g for 5 minutes.
The fraction of lymphocytes and monocytes obtained
according to this procedure was resuspended in medium
with 15% normal human serum (NHS) added to a con-
centration of 4 × 106 cells/ml. Flow cytometry (Epics XL-
MCL Beckman-Coulter, Florida, USA) analysis on these
cells by detection of cell surface CD14 and CD45 showed
that approximately 10% of the cells were monocytes. 800
µl of this cell-suspension was plated on a chamber slide 4
well glass slide (Nalge Nunc International, IL, USA) at
37°C in an atmosphere containing 5% CO2 and 96%
humidity for 1 h in order for the monocytes to adhere.
Nonadherent cells were removed by washing three times
with medium. Flow cytometry analysis of these nonadher-
ent cells showed that at least 90% were lymphocytes, and
were therefore used as source of lymphocytes. The cells
Relative P2 gene expression in CD34+ stem and progenitor cells Figure 3
Relative P2 gene expression in CD34+ stem and progenitor cells. A, Bar graph shows relative P2Y1, P2Y2, P2Y4, P2Y6, 
P2Y11, P2Y12 and P2Y13 receptor gene expression normalized to GAPDH. B, Bar graph shows relative P2X1, P2X4 and P2X7 
receptor gene expression normalized to GAPDH. P2Y1 was chosen to be calibrator.
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attached to the glass slides (<90% monocytes as assessed
by flow cytometry) were detached by adding first PBS and
then 0.5 mM EDTA-PBS for 3 min in room temperature.
Preparation of CD34+ stem and progenitor cells
Bone marrow samples were obtained from healthy volun-
teers (n = 3), after informed consent, using guidelines
approved by the Ethical Committee, Lund University.
Mononuclear cells were isolated by density gradient cen-
trifugation (Ficoll-Paque; Pharmacia, Uppsala, Sweden).
CD34+ cells were isolated by 2passages through magnetic
columns (MidiMacs;Miltenyi Biotec, Bergish Gladbach,
Germany) by using a hapten-conjugated CD34 antibody
(Qbend/10) and an antihapten antibody conjugated to
magnetic beads (CD34+ isolation kit; Miltenyi Biotec).
CD34 expression was analyzed by immunostaining with
a FACSCalibur flow cytometer (Becton Dickinson) by
using the CellQuest program (Becton Dickinson) and the
purity of isolated populations was reproducibly > 95%
[27].
RNA extraction
Total cellular RNAs were extracted using TRIzol reagent
(Gibco BRL, Life Technology) according to the supplier's
instructions, dissolved in diethyl-pyrocarbonate (DEPC)
treated water and stored at -70°C until used.
Quantitative analysis of P2 receptors by real-time reverse 
transcription polymerase chain reaction
TaqMan Reverse Transcription Reagents Kit was used to
transcribe mRNA into cDNA. Real-time PCR were
performed by means of a PRISM 7700Sequence Detector
as described previously [8,15,28,29]. Oligonucleotide
primers and TaqMan probes were designed using the
Primer Express software, based on sequences from the
GenBank database [8,15]. Constitutively expressed
GAPDH were selected as endogenous control to correct
for potential variation in RNA loading or efficiency of the
amplification reaction.
Previous analysis showed that amplification efficiencies
were almost identical for GADPH and the following
receptor mRNAs: P2Y1, P2Y2, P2Y4, P2Y6, P2Y11, P2Y12,
P2Y13, P2X1, P2X4, and P2X7  normalized to GAPDH
[8,15]. To confirm equal amplification efficiencies, we
used the criterion of a regression slope of less than 0.1 for
each gene normalized to GAPDH. This confirms that we
could use the comparative CT method for the relative
quantification of target without running standard curves
on the same plate (Perkin-Elmer Applied Biosystems Inc;
User Bulletin No. 2, December 1997). The amount of tar-
get and endogenous reference was determined from the
comparative CT method. The target gene normalized to
GAPDH was expressed as ∆CT (CT of target gene minus CT
of GAPDH). P2Y1 was arbitrarily chosen to be the calibra-
tor in the comparative analysis and is expressed as ∆CTP2Y1
(CT of target minus CT of GAPDH for P2Y1). The normal-
ized calibrated value is given by the equation 2-∆∆Ct, where
∆∆CT is ∆CT -∆CTP2Y1. To further verify the specificity of
PCR assays, the PCR was performed with non-reverse-
transcribed total cellular RNA and samples lacking the
DNA template. No significant amplifications were
obtained in any of these samples (data not shown).
Drugs
Unless otherwise stated, all reagents and drugs were pur-
chased from Sigma Chemical Corp, St. Louis, MI, USA.
PCR consumables were obtained from Perkin-Elmer
Applied Biosystems Inc, Foster City, CA, USA.
Statistical methods
Data are expressed as mean and standard error of the
mean (SEM) unless otherwise stated. n indicates the
number of subjects that were tested. Statistical analysis of
the normalized CT values (∆CT) was performed with a
one-way ANOVA, followed by a multiple comparison
post test (Tukey's test) using GraphPad InStat version 3.00
(GraphPad Software Inc., USA). Significant differences
were considered at P < 0.05 (two-tailed test).
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